CASI Pharmaceuticals - CASI Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI shares.
View CASI analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12 month price targets for CASI Pharmaceuticals' stock. Their CASI share price forecasts range from $12.00 to $21.00. On average, they anticipate the company's stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 529.8% from the stock's current price.
View analysts price targets for CASI or view top-rated stocks among Wall Street analysts.

CASI Pharmaceuticals' stock was trading at $8.00 at the beginning of the year. Since then, CASI shares have decreased by 67.3% and is now trading at $2.62.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our CASI earnings forecast.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) released its quarterly earnings data on Friday, November, 12th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.10. The biotechnology company earned $8.11 million during the quarter, compared to analyst estimates of $7.77 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 41.02% and a negative net margin of 91.97%. During the same quarter last year, the firm earned ($1.40) EPS.

Shares of CASI Pharmaceuticals reverse split on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Blockchain (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

CASI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (7.46%), Wellington Shields Capital Management LLC (1.57%), Wellington Shields & Co. LLC (1.07%), Ikarian Capital LLC (0.97%), State Street Corp (0.26%) and Bailard Inc. (0.23%). Insiders that own company stock include James Huang, Larry Zhang, Weihao Xu and Wei-Wu He.
View institutional ownership trends.

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CASI stock can currently be purchased for approximately $2.62.

CASI Pharmaceuticals (NASDAQ:CASI) has a market capitalization of $35.65 million and generates $30.17 million in revenue each year. The biotechnology company earns $-36,650,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

The company employs 176 workers across the globe.

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The official website for the company is www.casipharmaceuticals.com. The biotechnology company can be reached via phone at (240) 864-2600, via email at ir@casipharmaceuticals.com, or via fax at 301-315-2437.